

## **Associates of Cape Cod, Inc. to Market and Distribute Hyalose, L.L.C. Select-HA™ Products**

**East Falmouth, MA, Austin, TX and Oklahoma City, OK – May 31, 2005** – Associates of Cape Cod, Inc. (ACC) of East Falmouth, Massachusetts and Hyalose, L.L.C. of Oklahoma City, Oklahoma, have closed on a worldwide distribution agreement for the Hyalose Select-HA™ line of products. Select-HA™ is a proprietary and patent-protected series of recombinant hyaluronic acid (HA) of very well defined lengths and molecular weights, and is only available through Hyalose and ACC.

ACC will utilize its direct sales force as well as its vast array of worldwide distributors to sell the Select-HA™ line into the pharmaceutical, biotechnology, nutraceutical, tissue engineering and medical device industries.

HA, a naturally occurring substance produced in the body and found in the skin, joints and eyes, diminishes with age. HA made using Hyalose's recombinant technology results in a higher quality, more consistent product. Current uses for HA include the treatment of arthritis, and it is widely used in eye surgery, urology, wound healing, scar reduction applications, anti-wrinkle creams and cosmetics. Annual worldwide sales for products incorporating HA amount to more than \$3 billion.

Tommy Harlan, CEO of Hyalose, commented, "The Select-HA™ process was developed by Hyalose Chief Scientist Dr. Paul DeAngelis at the University of Oklahoma Health Sciences Center under an Oklahoma Applied Research Support (OARS) grant from the Oklahoma Center for the Advancement of Science and Technology (OCAST) which the company matched in 2002-2003. We are delighted that Select-HA™ products will now enjoy worldwide marketing and distribution through the ACC. The synergy between ACC's depth in distribution and market expertise, and our strength in leading-edge recombinant HA technology has created a partnership that can service the unique needs of customers in the varied industries we serve. We are pleased with the immediate worldwide market exposure that this provides for Hyalose, and we are very optimistic that Associates of Cape Cod will be a dominant player in the development of new markets for Select-HA™".

"ACC is pleased to add the Hyalose products to our portfolio of world class glycobiology reagents. We have been building on our commitment to becoming the premier provider of glycobiology products in the world" said President and Chief Executive Officer of ACC, Dr. A.J. Meuse. "With this partnership and the addition of the Hyalose Select-HA™ line, we will deliver considerable benefits to our pharmaceutical, nutraceutical and medical device customers who are seeking to optimize the results of their research and the performance of key products."

### **About Hyalose, L.L.C.**

Hyalose, L.L.C., was formed and capitalized in 2000 by Emergent Technologies, Inc. (ETI). Harlan founded ETI in 1989 and as its Chairman, CEO and President directs the activities of ETI and its eleven portfolio companies. ETI is a venture capital firm that specializes in forming, funding, commercializing and managing biotech companies for the purpose of converting institutional and university-based technology into high-return ventures. For more information on Hyalose, L.L.C. visit its website at [www.hyalose.com](http://www.hyalose.com). Visit ETI's website at [www.emergentechnologies.com](http://www.emergentechnologies.com)

Company and Media Contact: John Hoopingarner, (512) 263-3232 x 205

### **About Associates of Cape Cod, Inc.**

Associates of Cape Cod, Inc., based in East Falmouth, MA, is a leader in the field of bacterial endotoxin and beta-glucan detection. A wholly owned subsidiary of Seikagaku Corporation, the Company pioneered the use of Horseshoe Crab blood extract, *Limulus* Amebocyte Lysate (LAL), used in the testing of pharmaceuticals, medical devices and biologics, for the presence of potentially toxic endotoxins and glucans. In 1977 the Company was the first to receive an FDA license for the manufacture of this reagent. Products are marketed throughout the world under the trade names Pyrotell®, Glucatell®, Pyrochrome® and Chromo-LAL. The Company also offers a contract testing service for endotoxin and glucan detection, and has a research biochemical division specializing in carbohydrate chemistry. For more information about Associates of Cape Cod, Inc. and available products, please visit the corporate website at: <http://www.acciusa.com>.

Media Contact: Amy B. Tarbox, [press@acciusa.com](mailto:press@acciusa.com)  
Company Contact: Debbie Fraser, (508) 540-3808 x 2228

Keywords : Glycosaminoglycans, Hyaluronic Acid, hyaluronan, glycobiology, pharmaceutical, biotechnology, nutraceutical, tissue engineering, medical device industries.